Sorbent Therapeutics has drawn down the first $6.5 million tranche of a $15 million venture round to finance a Phase IIb trial of its experimental heart therapy and has finished enrolling 275 patients in the Phase IIb study, which will test CLP-1001.

…read more

Source: Novartis-backed Sorbent grabs first tranche in $15M heart therapy round


0 No comments